Dr. Verma on Immunotherapy in HER2+ Breast Cancer – OncLive
|
Dr. Verma on Immunotherapy in HER2+ Breast Cancer
OncLive Additionally, there is interest in testing immunotherapy combinations in the neoadjuvant setting. The goal in introducing checkpoint inhibitors is to move further away from treatment with chemotherapy, Verma says. Generally, it is thought that a … |
